Abstract
Anderson-Fabry disease (AFD) is a lysosomal storage disease caused by the inappropriate accumulation of globotriaosylceramide in tissues due to a deficiency in the enzyme α-galactosidase A (α-Gal A). Anderson-Fabry cardiomyopathy is characterized by structural, valvular, vascular and conduction abnormalities, and is now the most common cause of mortality in patients with AFD. Large-scale metabolic and genetic screening studies have revealed AFD to be prevalent in populations of diverse ethnic origins, and the variant form of AFD represents an unrecognized health burden. Anderson-Fabry disease is an X-linked disorder, and genetic testing is critical for the diagnosis of AFD in women. Echocardiography with strain imaging and cardiac magnetic resonance imaging using late enhancement and T1 mapping are important imaging tools. The current therapy for AFD is enzyme replacement therapy (ERT), which can reverse or prevent AFD progression, while gene therapy and the use of molecular chaperones represent promising novel therapies for AFD. Anderson-Fabry cardiomyopathy is an important and potentially reversible cause of heart failure that involves LVH, increased susceptibility to arrhythmias and valvular regurgitation. Genetic testing and cardiac MRI are important diagnostic tools, and AFD cardiomyopathy is treatable if ERT is introduced early.
Similar content being viewed by others
References
Clarke JT (2007) Narrative review: Fabry disease. Ann Intern Med 146:425–433
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med 345:9–16
Rao DA, Lakdawala NK, Miller AL, Loscalzo J (2013) Clinical problem-solving. In the thick of it. N Engl J Med 368:1732–1738
Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S et al (2013) The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the world heart federation. J Am Coll Cardiol 62:2046–2072
Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy—a retrospective analysis from the Fabry outcome survey. Clin J Pain 23:535–542
Keshav S (2006) Gastrointestinal manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS, chap 28. Oxford PharmaGenesis, Oxford
Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G et al (2007) Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 157:331–337
Samiy N (2008) Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 53:416–423
Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS—Fabry outcome survey. J Med Genet 46:548–552
Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E et al (2009) Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transpl 24:1736–1743
Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ (2000) Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 48:227–235
Germain DP (2001) A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib Nephrol (136): 234–240
Grunfeld JP, Lidove O, Joly D, Barbey F (2001) Renal disease in Fabry patients. J Inherit Metab Dis 24(Suppl 2):71–74
Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S139–S143
Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D et al (2000) New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J 139:1101–1108
Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J et al (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24(Suppl 2):75–83
Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Arnao V, Licata G et al (2013) Neurological complications of Anderson-Fabry disease. Curr Pharm Des 19:6014–6030
Elleder M, Dorazilova V, Bradova V, Belohlavek M, Kral V, Choura M et al (1990) Fabry’s disease with isolated disease of the cardiac muscle, manifesting as hypertrophic cardiomyopathy. Cas Lek Cesk 129:369–372
von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG et al (1991) An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 324:395–399
Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M et al (1995) An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 333:288–293
Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228–1235
Mignani R, Feriozzi S, Schaefer RM, Breunig F, Oliveira JP, Ruggenenti P et al (2010) Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy. Clin J Am Soc Nephrol 5:379–385
Scriver CR (1995) The metabolic and molecular bases of inherited disease, vol II. McGraw-Hill, New York, p 2742
Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S (2013) Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 58:548–552
Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A et al (2012) Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 379:335–341
Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH et al (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2:450–456
Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40
Feldt-Rasmussen U, Dobrovolny R, Nazarenko I, Ballegaard M, Hasholt L, Rasmussen AK et al (2011) Diagnostic dilemma: a young woman with Fabry disease symptoms, no family history, and a “sequencing cryptic” alpha-galactosidase a large deletion. Mol Genet Metab 104:314–318
Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ et al (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407–1411
Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA et al (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110:1047–1053
Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB et al (2011) Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry disease survey. Heart 97:1957–1960
Havndrup O, Christiansen M, Stoevring B, Jensen M, Hoffman-Bang J, Andersen PS et al (2010) Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail 12:535–540
van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE et al (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51:1–9
Bach G, Rosenmann E, Karni A, Cohen T (1982) Pseudodeficiency of alpha-galactosidase A. Clin Genet 21:59–64
Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ (2003) Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 22:486–492
Niemann M, Rolfs A, Stork S, Bijnens B, Breunig F, Beer M et al (2014) Gene mutations versus clinically relevant phenotypes-Lyso-Gb3 defines fabry disease. Circ Cardiovasc Genet 7:8–16
MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775
Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112–128
Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J et al (2013) Fabry disease practice guidelines: recommendations of the national society of genetic counselors. J Genet Couns 22:555–564
Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34–45
Juan P, Hernan A, Beatriz SA, Gustavo C, Antonio M, Eduardo T et al (2014) Fabry Disease: multidisciplinary evaluation after 10 years of treatment with agalsidase beta. JIMD Rep. doi:10.1007/8904_2014_310
Anderson LJ, Wyatt KM, Henley W, Nikolaou V, Waldek S, Hughes DA et al (2014) Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. doi:10.1007/s10545-014-9717-4
Desnick RJ (2007) Prenatal diagnosis of Fabry disease. Prenat Diagn 27:693–694
Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077–1084
Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524–529
Shin SH, Kluepfel-Stahl S, Cooney AM, Kaneski CR, Quirk JM, Schiffmann R et al (2008) Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Pharmacogenet Genomics 18:773–780
Linhart A (2006) The heart in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS, chap 20. Oxford PharmaGenesis, Oxford
Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M et al (2010) Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 31:1088–1097
Sadick N, Thomas L (2007) Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study. Heart Lung Circ 16:200–206
Shanks M, Thompson RB, Paterson ID, Putko B, Khan A, Chan A et al (2013) Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. J Am Soc Echocardiogr 26:1407–1414
Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M et al (2011) Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 4:592–601
Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I et al (2013) T1 mapping with cardiovascular MRI is highly sensitive for fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 6:637–645
Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M et al (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40:1668–1674
Gambarin FI, Disabella E, Narula J, Diegoli M, Grasso M, Serio A et al (2010) When should cardiologists suspect Anderson-Fabry disease? Am J Cardiol 106:1492–1499
Calcagnino M, O’Mahony C, Coats C, Cardona M, Garcia A, Janagarajan K et al (2011) Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease. J Am Coll Cardiol 58:88–89
Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307:491–497
Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA 307:483–490
Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A et al (2013) Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310:959–968
Kalliokoski RJ, Kalliokoski KK, Sundell J, Engblom E, Penttinen M, Kantola I et al (2005) Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 28:563–573
Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357–360
Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S et al (2006) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26:839–844
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812–2817
Pochis WT, Litzow JT, King BG, Kenny D (1994) Electrophysiologic findings in Fabry’s disease with a short PR interval. Am J Cardiol 74:203–204
Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96:842–846
Eckart RE, Kinney KG, Belnap CM, Le TD (2000) Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry’s disease. Review of cardiovascular manifestations. Cardiology 94:208–212
Acharya D, Robertson P, Kay GN, Jackson L, Warnock DG, Plumb VJ et al (2012) Arrhythmias in Fabry cardiomyopathy. Clin Cardiol 35:738–740
Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97:463–469
Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A (2003) Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107:1978–1984
Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, Pintos G et al (2009) Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 132:38–44
Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221–1227
Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108:1299–1301
Soullier C, Obert P, Doucende G, Nottin S, Cade S, Perez-Martin A et al (2012) Exercise response in hypertrophic cardiomyopathy: blunted left ventricular deformational and twisting reserve with altered systolic-diastolic coupling. Circ Cardiovasc Imaging 5:324–332
Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ et al (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24:2151–2155
Koeppe S, Neubauer H, Breunig F, Weidemann F, Wanner C, Sandstede J et al (2012) MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease. Int J Cardiol 160:53–58
Messalli G, Imbriaco M, Avitabile G, Russo R, Iodice D, Spinelli L et al (2012) Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. Radiol Med 117:19–28
Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA (2011) Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 57:891–903
Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G et al (2013) Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 6:392–398
Desnick RJ, Wasserstein MP, Banikazemi M (2001) Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy. Contrib Nephrol (136):174–192
Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L et al (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711–722
Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86
Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE et al (2010) Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 5:2220–2228
Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M et al (2004) Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15:1323–1329
University of Alabama at Birmingham. The Fabrazyme and ARBs and ACE Inhibitor Treatment (FAACET) Study. http://www.clinicaltrials.gov/ct2/show/NCT00446862. Accessed July 2 2014
Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H (1967) Angiokeratoma corporis diffusum–Fabry’s disease. Helv Med Acta 34:67–83
MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760
Tyson CC, Nwankwo C, Lin PH, Svetkey LP (2012) The dietary approaches to stop hypertension (DASH) eating pattern in special populations. Curr Hypertens Rep 14:388–396
Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539–548
West ML, Casey R, Clarke JT, Iwanochko M, Moore DF, Sirrs S (2012) Canadian Fabry disease treatment guidelines 2012. http://www.garrod.ca/wp-content/uploads/Canadian-FD-Treatment-Guidelines-2012.pdf. Accessed July 2 2014
Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O’Callaghan MW (2009) Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119:2561–2567
Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M et al (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97:365–370
Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374:1986–1996
Alfadhel M, Sirrs S (2011) Enzyme replacement therapy for Fabry disease: some answers but more questions. Ther Clin Risk Manag 7:69–82
Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE (2014) Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis 37:341–352
Pieroni M, Camporeale A, Della Bona R, Sabini A, Cosmi D, Magnolfi A et al (2013) Progression of Fabry cardiomyopathy despite enzyme replacement therapy. Circulation 128:1687–1688
Weidemann F, Niemann M, Stork S, Breunig F, Beer M, Sommer C et al (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274:331–341
Hersher R (2012) Small biotechs raring to cash in on the orphan disease market. Nat Med 18:330–331
Murray GJ, Anver MR, Kennedy MA, Quirk JM, Schiffmann R (2007) Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 90:307–312
El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2:CD006663
Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S et al (2014) Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab 111:499–506
Guce AI, Clark NE, Rogich JJ, Garman SC (2011) The molecular basis of pharmacological chaperoning in human alpha-galactosidase. Chem Biol 18:1521–1526
Suzuki Y (2013) Chaperone therapy update: fabry disease, GM1-gangliosidosis and Gaucher disease. Brain Dev 35:515–523
Benjamin ER, Khanna R, Schilling A, Flanagan JJ, Pellegrino LJ, Brignol N et al (2012) Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther 20:717–726
Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M et al (2001) Improvement in cardiac function in the cardiac variant of Fabry’s disease with galactose-infusion therapy. N Engl J Med 345:25–32
Wu X, Katz E, Della Valle MC, Mascioli K, Flanagan JJ, Castelli JP et al (2011) A pharmacogenetic approach to identify mutant forms of alpha-galactosidase A that respond to a pharmacological chaperone for Fabry disease. Hum Mutat 32:965–977
Siekierska A, De Baets G, Reumers J, Gallardo R, Rudyak S, Broersen K et al (2012) Alpha-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. J Biol Chem 287:28386–28397
Lee CJ, Fan X, Guo X, Medin JA (2011) Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease. J Cardiol 57:115–122
Ruiz de Garibay AP, Delgado D, Del Pozo-Rodriguez A, Solinis MA, Gascon AR (2012) Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy. Drug Des Devel Ther 6:303–310
Acknowledgments
Brendan Putko is partially supported by a studentship award from the Alberta HEART STEADI-HF training program, and Gavin Y. Oudit is supported by operating grants from the Canadian Institute of Health Research and the Heart and Stroke Foundation of Canada.
Conflict of interest
Gavin Y. Oudit has received research funding from Pfizer and Glaxo-Smith Kline.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Putko, B.N., Wen, K., Thompson, R.B. et al. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. Heart Fail Rev 20, 179–191 (2015). https://doi.org/10.1007/s10741-014-9452-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-014-9452-9